DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Patidegib

Generic Name: Patidegib

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₄₈N_₂O_₃S

CAS Number: 1037210-93-7

Unique Ingredient Identifier: JT96FPU35X

Overview

Patidegib has been investigated for the treatment of Conventional Chondrosarcoma.

Background

Patidegib has been investigated for the treatment of Conventional Chondrosarcoma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome

Phase 3

Recruiting

Posted: 2023/09/22

Sponsor:Sol-Gel Technologies...

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Phase 3

Terminated

Posted: 2020/03/16

Sponsor:Sol-Gel Technologies...

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Phase 2

Terminated

Posted: 2019/11/07

Sponsor:Sol-Gel Technologies...

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Phase 3

Completed

Posted: 2018/10/11

Sponsor:Sol-Gel Technologies...

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

Phase 2

Completed

Posted: 2016/07/11

Sponsor:PellePharm, Inc.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Sol-Gel and Mayne Pharma Announce $16 Million Deal for EPSOLAY and TWYNEO Rights in the U.S.

a month ago

Sol-Gel Technologies has entered into a $16 million agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to dermatology products EPSOLAY and TWYNEO, extending the company's cash runway into Q1 2027.

Sol-Gel Technologies Receives Nasdaq Extension to Regain Compliance

6 months ago

Sol-Gel Technologies received a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, now until May 19, 2025.

Sol-Gel Technologies Advances SGT-610 for Gorlin Syndrome and SGT-210 for Darier Disease

6 months ago

Sol-Gel's Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is actively enrolling patients across 40 clinical sites, with topline results expected in H2 2026.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy